Michael R. Dyson
Cambridge, ENG CB223AT, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Generation of high-expressing transposon-based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies.
Journal: Biotechnology progress
Published: October 28, 2025
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Journal: Nature cancer
Published: October 09, 2023
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
Journal: Nature communications
Published: July 31, 2023
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.
Journal: Nature communications
Published: March 21, 2022
High-Throughput Expression Screening in Mammalian Suspension Cells.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: October 30, 2020
Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.
Journal: mAbs
Published: October 26, 2020
Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?
Journal: Annals of the rheumatic diseases
Published: August 16, 2018
Fundamentals of Expression in Mammalian Cells.
Journal: Advances in experimental medicine and biology
Published: May 12, 2016
Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2).
Journal: The Biochemical journal
Published: July 06, 2015
Last Updated: 09/26/2026